Quigley Secures $25 Million for ALS Research

U.S. Representative Mike Quigley (IL-05), Chairman of the Financial Services and General Government Appropriations Subcommittee, announced the inclusion of $25 million to begin implementation of the Accelerating Access to Critical Therapies for ALS Act, or ACT for ALS, in the Fiscal Year 2022 Omnibus Appropriations Act, which passed the House of Representatives last night. In May 2021, Congressman Quigley introduced ACT for ALS, which was signed into law by President Biden in December. This bipartisan, bicameral legislation will help people living with ALS get early access to promising treatments and help researchers gain a better understanding of neurodegenerative diseases.

This is a robust down payment on a program that will help build a strong research and development infrastructure to develop treatments and cures for ALS by helping patients get access to promising treatments today.

"Watching President Biden sign this bill into law was a victory for every person suffering from ALS, their families, and those who may be diagnosed. The passage of this funding means we can now implement this transformative legislation to accelerate the search for therapies and cures to end ALS once and for all," said Quigley. "We look forward to working closely with NIH and FDA to implement ACT for ALS in line with congressional intent. I will continue to work to secure full funding for this vitally important program."